Free Trial

Cellectis (CLLS) Competitors

Cellectis logo
$3.98 -0.54 (-11.95%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$4.09 +0.11 (+2.76%)
As of 10/17/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLLS vs. VALN, PROK, ANAB, KURA, AVBP, PHAT, CRMD, MRVI, VIR, and DNA

Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Valneva (VALN), ProKidney (PROK), AnaptysBio (ANAB), Kura Oncology (KURA), ArriVent BioPharma (AVBP), Phathom Pharmaceuticals (PHAT), CorMedix (CRMD), Maravai LifeSciences (MRVI), Vir Biotechnology (VIR), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

Cellectis vs. Its Competitors

Valneva (NASDAQ:VALN) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Valneva has a net margin of -33.87% compared to Cellectis' net margin of -100.69%. Valneva's return on equity of -34.78% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Valneva-33.87% -34.78% -13.43%
Cellectis -100.69%-68.05%-21.53%

Valneva has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500.

Valneva currently has a consensus target price of $15.00, suggesting a potential upside of 49.09%. Cellectis has a consensus target price of $8.00, suggesting a potential upside of 101.01%. Given Cellectis' higher possible upside, analysts plainly believe Cellectis is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cellectis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Valneva and Valneva both had 6 articles in the media. Valneva's average media sentiment score of 0.35 beat Cellectis' score of 0.35 indicating that Valneva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Valneva
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cellectis
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

11.4% of Valneva shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valneva has higher revenue and earnings than Cellectis. Valneva is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valneva$183.52M4.71-$13.25M-$0.98-10.27
Cellectis$49.22MN/A-$36.76M-$0.82-4.85

Summary

Valneva beats Cellectis on 8 of the 14 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLLS vs. The Competition

MetricCellectisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$251.24M$3.39B$6.09B$10.49B
Dividend YieldN/A2.28%5.73%4.80%
P/E Ratio-4.8522.4484.7527.11
Price / SalesN/A267.64519.29179.59
Price / CashN/A46.5937.1661.22
Price / Book1.6910.4112.246.52
Net Income-$36.76M-$52.47M$3.33B$276.84M
7 Day Performance-1.49%2.32%1.19%1.95%
1 Month Performance25.95%11.14%6.18%2.21%
1 Year Performance108.38%11.15%59.89%34.06%

Cellectis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLLS
Cellectis
1.9034 of 5 stars
$3.98
-11.9%
$8.00
+101.0%
+108.4%$251.24M$49.22M-4.85290News Coverage
Positive News
Analyst Forecast
Gap Up
VALN
Valneva
2.9238 of 5 stars
$10.50
+1.3%
$15.00
+42.9%
+79.0%$891.07M$183.52M-10.71700Short Interest ↓
PROK
ProKidney
2.3685 of 5 stars
$2.99
-1.0%
$6.25
+109.0%
+50.0%$888.73M$80K-5.253Gap Down
ANAB
AnaptysBio
2.8787 of 5 stars
$32.46
+3.5%
$52.00
+60.2%
-1.6%$878.27M$91.28M-7.25100Trending News
Analyst Forecast
Analyst Revision
KURA
Kura Oncology
4.1638 of 5 stars
$9.93
+0.8%
$24.10
+142.7%
-45.6%$854.95M$53.88M-4.39130Gap Down
AVBP
ArriVent BioPharma
1.4476 of 5 stars
$20.90
+0.2%
$39.14
+87.3%
-32.7%$846.27MN/A-5.2040
PHAT
Phathom Pharmaceuticals
2.9817 of 5 stars
$12.53
+6.0%
$17.50
+39.7%
-20.2%$838.55M$55.25M-2.65110News Coverage
Analyst Upgrade
CRMD
CorMedix
3.2918 of 5 stars
$10.58
-1.4%
$18.00
+70.1%
-3.0%$837.57M$43.47M14.1130
MRVI
Maravai LifeSciences
3.7784 of 5 stars
$3.30
+3.4%
$5.22
+58.1%
-59.3%$814.60M$259.18M-2.43610News Coverage
Analyst Forecast
Options Volume
VIR
Vir Biotechnology
3.5538 of 5 stars
$5.86
+1.0%
$17.30
+195.2%
-25.1%$805.72M$74.21M-1.47580News Coverage
Analyst Forecast
Insider Trade
DNA
Ginkgo Bioworks
1.2548 of 5 stars
$13.20
-2.4%
$9.00
-31.8%
+58.4%$800.38M$227.04M-2.25640

Related Companies and Tools


This page (NASDAQ:CLLS) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners